Atrophic Gastritis Treatment Market Predicts Favorable Growth and Forecast Till 2025

Atopic gastritis is chronic inflammation of gastric mucosa, and it is a histopathological condition associated with gastric glandular cell and replacement by fibrous tissue, intestinal type epithelium, and pyloric type glands. It mainly associated H. Pylori bacterial infection, and autoimmunity directed against gastric glandular cell. Symptoms include stomach pain, loss of appetite, nausea, unexpected weight loss, iron deficiency anemia. There is a high chance for the development of pernicious anemia in autoimmune atrophic gastritis Individual due to the loss of anti-intrinsic antibodies and parietal cell mass.

Atrophic gastritis associated with H. Pylori are at high risk of developing gastric carcinoma and is frequently asymptomatic. Individuals associated with chronic atrophic gastritis develop hypergastrinemia and low gastric acid output which may lead to carcinoid tumors and enterochromaffin-like cell hyperplasia. Atrophic gastritis develops at childhood and if, it is left untreated atrophic gastritis progress throughout the lifespan. Treatment mainly includes antibiotics for eliminating H. Pylori bacteria. Symptomatic treatment includes vitamin B-12 injections. Proton pump inhibitors used to control the acidity of the stomach. Autoimmune atrophic gastritis associated with gastric polyps, pernicious anemia, and adenocarcinoma. Atrophic gastritis diagnosed by low levels of B-12, low levels of pepsinogen, high levels of gastrin and intrinsic factors.

Atrophic Gastritis treatment Market: Drivers and Restraints

Atrophic gastritis is associated with loss of gastric gland and is a progressive condition with the replacement of metaplasia. It is asymptomatic and associated with large complications like gastric carcinoma, hyperplasia, hypergastrinemia, increased risk of heart attack in elderly. The frequency of atrophic gastritis is unknown due to it is mostly asymptomatic. Atrophic gastritis is extremely common and is highly prevalent in different parts of the globe. In atrophic gastritis, eradication of H. Pylori is highly complicated, and it requires follow-up for several years. Eradication of H. Pylori reduces the risk of developing cancers in late stages. Mortality and morbidity associated with atrophic gastritis are depended on underlying complications of diseases. Atrophic gastritis requires a continuous management because recurrence of illness is high. All these factors act as a driver in the robust growth of the atrophic gastritis treatment market.

Antibiotic resistance and lack of patient compliance are main factors associated with poor outcomes of the treatment. These factors are also affecting the growth of the atrophic gastritis treatment market.

Atrophic Gastritis treatment Market: Market Overview

Global Atrophic Gastritis treatment market witnessed rapid growth due to rising demand for potential health benefits. Manufacturers shifted towards Bismuths containing drugs due to the high resistance to traditional medicines. In most of the case, triple therapy (Combinations of three different type of antibiotics) is administered. The rate of antibiotic resistance is also increasing with usage and manufacturers are more focused towards developing combination therapy. The future of Atrophic Gastritis treatment market is anticipated to grow at double CAGR during the forecast period.

Atrophic Gastritis treatment Market: Region-wise Overview

Global Atrophic Gastritis treatment Market segmented into North America, Europe, Asia -Pacific & Japan, The Middle East and Africa regions and Latin America by region wise. North America dominates the global Atrophic Gastritis treatment Market due to the high awareness among the patients, and in North America, USA is a major stakeholder due to the strong players. Europe and Asia-pacific are the fastest growing market in Atrophic Gastritis treatment Market due to high incidence. The economic conditions in Asia-pacific region rise the Atrophic Gastritis treatment market to new heights. The Middle East and Africa regions and Latin America are also showing significantly less growth because of less knowledge regarding Atrophic Gastritis treatment during the forecasted period.

Request for more detailed information (TOC And Sample) : https://www.persistencemarketresearch.com/samples/17524

Atrophic Gastritis treatment Market: Key Participants

The key participants in Atrophic Gastritis treatment Market are Takeda Pharmaceutical Company Limited, PERNIX Therapeutics, Perrigo Pharmaceutical, Teva Pharmaceutical, and Others. The companies are mainly focusing on intense marketing to convey health benefits of atrophic gastritis treatment market.

To Know About Latest Report Click Here: https://www.persistencemarketresearch.com/market-research/atrophic-gastritis-treatment-market.asp

About Us 
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
 PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact
Persistence Market Research Pvt. Ltd
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
media@persistencemarketresearch.com
Web:www.persistencemarketresearch.com

This release was published on openPR.